Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 666
- 试验地点
- 13
- 主要终点
- 30-day all-cause mortality
研究概览
简要总结
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
详细描述
This is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in the online data collection form in a de-identified manner. This form includes questions about general clinical history of hematologic disease, manifestation, treatment, and the course of COVID-19, concomitant conditions, consequences on the hematologic disease, short-term and long-term outcomes. It will take approximately 10 min to answer the questions. Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for hematologic disease outcomes and overall survival assessment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
30-day all-cause mortality
时间窗: 30 day
Rate of death from any cause
次要结局
- Relapse or progression of hematologic disease(30 day, 90 day and 180 day)
- Overall survival(30 day, 90 day and 180 day)
- ICU admission(30 day)
- COVID-19 complications(30 day)
- Mechanical ventilation / O2 requirement(30 day)
- Risk factors(30 day, 90 day and 180 day)